MedTrace Logo

A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant

NCT02436460 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-03-30

No results posted yet for this study

Summary

This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in patients with steroid-refractory aGVHD following allogeneic hematopoietic cell transplantation administered AbGn-168H once weekly for 4 weeks.

Conditions

  • Acute Graft Versus Host Disease

Interventions

BIOLOGICAL

AbGn-168H

Humanized monoclonal antibody

Sponsors & Collaborators

  • AbGenomics B.V Taiwan Branch

    lead INDUSTRY

Principal Investigators

  • Shih-Yao (David) Lin, MD, PhD · AbGenomics B.V.

  • Everett Meyer, MD · Stanford University Hospitals and Clinics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436460 on ClinicalTrials.gov